Patients with type 2 diabetes initiating exenatide twice daily or insulin in clinical practice: CHOICE study

Diabetes Therapy

Volumn 3, Issue 1, 2012, Pages 1-15

  Matthaei, Stephan ^a   Reaney, Matthew ^b   Mathieu, Chantal ^c   Östenson, Claes Göran ^d   Krarup, Thure ^e   Guerci, Bruno ^f   Kiljanski, Jacek ^g   Petto, Helmut ^h   Bruhn, David ⁱ   Theodorakis, Michael ^j  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

^e BISPEBJERG HOSPITAL   (Denmark)

^f CHU NANCY BRABOIS   (France)

^g Eli Lilly Polska Sp z oo   (Poland)

^h ELI LILLY   (Austria)

ⁱ Eli Lilly   (United States)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

Exenatide; Insulin; Type 2 diabetes mellitus

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CREATININE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; EDUCATIONAL STATUS; EUROPE; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84863903161     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0006-7     Document Type: Article

References (21)

1. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143: 559-69.
2. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29: 2333-48.
3. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-67.
4. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24: 275-86.
5. Ligthelm RJ, Borzi{dotless} V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29: 1284-92.
6. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20:54-60.
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
8. Meadows K, Abrams S, Sandback A. Adaptation of the diabetes health profile (DHP-1) for use with patients with type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison. Diabet Med. 2000;17:572-80.
9. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25:691-700.
10. PHARMO report: treatment pathways of type 2 DM patients starting insulin regimens. Utrecht, The Netherlands, January 2007 (Lilly, data on file).
11. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17:1-13.
12. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
13. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007;22:453-8.
14. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412-8.
15. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
16. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25: 777-86.
17. Buse JB, Henry RR, J, et al. Effects of exenatide on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
18. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
19. Buysschaert M, Preumont V, Oriot PR, et al. One year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36:381-8.
20. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
21. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.